These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38443618)

  • 21. COVID-19 among workers of a comprehensive cancer centre between first and second epidemic waves (2020): a seroprevalence study in Catalonia, Spain.
    Peremiquel-Trillas P; Saura-Lázaro A; Benavente-Moreno Y; Casabonne D; Loureiro E; Cabrera S; Duran A; Garrote L; Brao I; Trelis J; Galán M; Soler F; Julià J; Cortasa D; Domínguez MÁ; Albasanz-Puig A; Gudiol C; Ramírez-Tarruella D; Muniesa J; Rivas JP; Muñoz-Montplet C; Sedano A; Plans À; Calvo-Cerrada B; Calle C; Clopés A; Carnicer-Pont D; Alemany L; Fernández E
    BMJ Open; 2022 Apr; 12(4):e056637. PubMed ID: 35450905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Parallel evolution and differences in seroprevalence of SARS-CoV-2 antibody between patients with cancer and health care workers in a tertiary cancer centre during the first and second wave of COVID-19 pandemic: canSEROcov-II cross-sectional study.
    Ladoire S; Rederstorff E; Goussot V; Parnalland S; Briot N; Ballot E; Truntzer C; Ayati S; Bengrine-Lefevre L; Bremaud N; Coudert B; Desmoulins I; Favier L; Fraisse C; Fumet JD; Hennequin A; Hervieu A; Ilie S; Kaderbhai C; Lagrange A; Martin N; Mazilu I; Mayeur D; Palmier R; Simonet-Lamm AL; Vincent J; Zanetta S; Arnould L; Coutant C; Bertaut A; Ghiringhelli F
    Eur J Cancer; 2022 Apr; 165():13-24. PubMed ID: 35189537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SARS-CoV-2 seroprevalence in healthcare workers of a teaching hospital in a highly endemic region in the Netherlands after the first wave: a cross-sectional study.
    Bouwman M; van Osch F; Crijns F; Trienekens T; Mehagnoul-Schipper J; van den Bergh JP; de Vries J
    BMJ Open; 2021 Oct; 11(10):e051573. PubMed ID: 34663664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SARS-CoV-2 seroprevalence and antibodies persistence among health care workers after the first COVID-19 wave in nine hospitals in Western France.
    Garlantezec R; Tadié E; Heslan C; Gary-Bobo P; Oumari S; Saade A; Sitruk A; Tattevin P; Thibault V; Paris C;
    Infect Dis Now; 2022 Nov; 52(8):447-452. PubMed ID: 36108975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Authors' response: Occupation and SARS-CoV-2 infection risk among workers during the first pandemic wave in Germany: potential for bias.
    Reuter M; Rigó M; Formazin M; Liebers F; Latza U; Castell S; Jöckel KH; Greiser KH; Michels KB; Krause G; Albrecht S; Öztürk I; Kuss O; Berger K; Lampl BMJ; Leitzmann M; Zeeb H; Starke KR; Schipf S; Meinke-Franze C; Ahrens W; Seidler A; Klee B; Pischon T; Andreas Deckert AD; Schmidt B; Mikolajczyk R; Karch A; Bohn B; Brenner H; Holleczek B; Dragano N
    Scand J Work Environ Health; 2022 Sep; 48(7):588-590. PubMed ID: 36153787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cross-sectional study evaluating the seroprevalence of SARS-CoV-2 antibodies among healthcare workers and factors associated with exposure during the first wave of the COVID-19 pandemic in New York.
    Bryan A; Tatem K; Diuguid-Gerber J; Cooke C; Romanoff A; Choudhury N; Scanlon M; Kishore P; Sydney E; Masci J; Bakshi P; Pemmasani S; Davis NJ; Maru D
    BMJ Open; 2021 Nov; 11(11):e053158. PubMed ID: 34732494
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies in the Mozambican Population: A Cross-Sectional Serologic Study in 3 Cities, July-August 2020.
    Arnaldo P; Mabunda N; Young PW; Tran T; Sitoe N; Chelene I; Nhanombe A; Ismael N; Júnior A; Cubula B; Inlamea OF; Gudo E; Jani IV
    Clin Infect Dis; 2022 Oct; 75(Suppl 2):S285-S293. PubMed ID: 35748663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SARS-CoV-2 Seroprevalence Among Healthcare Workers by Workplace Exposure Risk in Kashmir, India.
    Khan MS; Haq I; Qurieshi MA; Majid S; Bhat AA; Qazi TB; Chowdri IN; Sabah I; Kawoosa MF; Lone AA; Nabi S; Sumji IA; Obaid M; Kousar R
    J Hosp Med; 2021 May; 16(5):274-281. PubMed ID: 33929947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantification of Occupational and Community Risk Factors for SARS-CoV-2 Seropositivity Among Health Care Workers in a Large U.S. Health Care System.
    Baker JM; Nelson KN; Overton E; Lopman BA; Lash TL; Photakis M; Jacob JT; Roback JD; Fridkin SK; Steinberg JP
    Ann Intern Med; 2021 May; 174(5):649-654. PubMed ID: 33513035
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SARS-CoV-2 Antibody Testing in Health Care Workers: A Comparison of the Clinical Performance of Three Commercially Available Antibody Assays.
    Allen N; Brady M; Carrion Martin AI; Domegan L; Walsh C; Houlihan E; Kerr C; Doherty L; King J; Doheny M; Griffin D; Molloy M; Dunne J; Crowley V; Holmes P; Keogh E; Naughton S; Kelly M; O'Rourke F; Lynagh Y; Crowley B; de Gascun C; Holder P; Bergin C; Fleming C; Ni Riain U; Conlon N;
    Microbiol Spectr; 2021 Oct; 9(2):e0039121. PubMed ID: 34585976
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study.
    Regev-Yochay G; Lustig Y; Joseph G; Gilboa M; Barda N; Gens I; Indenbaum V; Halpern O; Katz-Likvornik S; Levin T; Kanaaneh Y; Asraf K; Amit S; Rubin C; Ziv A; Koren R; Mandelboim M; Tokayer NH; Meltzer L; Doolman R; Mendelson E; Alroy-Preis S; Kreiss Y
    Lancet Microbe; 2023 May; 4(5):e309-e318. PubMed ID: 36963419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High prevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies among unvaccinated children of Chandigarh, Northwest India, in a household-based paediatric serosurvey post-second wave of pandemic (June to July 2021).
    Ghosh A; Goyal K; Singh R; Lakshmi PVM; Kaur R; Kumar V; Muralidharan J; Puri GD; Ram J; Singh MP
    Public Health; 2023 Dec; 225():160-167. PubMed ID: 37931485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High anti-SARS-CoV-2 antibody seroconversion rates before the second wave in Manaus, Brazil, and the protective effect of social behaviour measures: results from the prospective DETECTCoV-19 cohort.
    Lalwani P; Araujo-Castillo RV; Ganoza CA; Salgado BB; Pereira Filho IV; da Silva DSS; de Morais TBDN; Jordão MF; Ortiz JV; Barbosa ARC; Sobrinho WBS; Cordeiro IB; de Souza Neto JN; de Assunção EN; da Costa CF; de Souza PE; de Albuquerque BC; Astofi-Filho S; ; Lalwani JDB
    Lancet Glob Health; 2021 Nov; 9(11):e1508-e1516. PubMed ID: 34678195
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of SARS-CoV-2 antibodies among North Dakota community pharmacy personnel: A seroprevalence survey.
    Johnson A; Vincent B; Carson P; Skoy E
    J Am Pharm Assoc (2003); 2021; 61(3):e127-e132. PubMed ID: 33568267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021.
    Tunheim G; Rø GØI; Chopra A; Aase A; Kran AB; Vaage JT; Lund-Johansen F; Hungnes O
    Influenza Other Respir Viruses; 2022 Nov; 16(6):1004-1013. PubMed ID: 35770841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High SARS-CoV-2 Prevalence among Healthcare Workers in Cochabamba, Bolivia.
    Saba Villarroel PM; Castro Soto MDR; Undurraga V; Sanz H; Jaldín AM; Ninove L; Nurtop E; Pezzi L; Mohamed Ali S; Amroun A; Seston M; de Lamballerie X
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in France: a cross-sectional study.
    Beaumont A; Durand C; Ledrans M; Schwoebel V; Noel H; Le Strat Y; Diulius D; Colombain L; Médus M; Gueudet P; Mouly D; Aumaître H
    BMJ Open; 2021 Nov; 11(11):e053201. PubMed ID: 34815286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.
    Charlton CL; Nguyen LT; Bailey A; Fenton J; Plitt SS; Marohn C; Lau C; Hinshaw D; Lutsiak C; Simmonds K; Kanji JN; Zelyas N; Lee N; Mengel M; Tipples G
    Microbiol Spectr; 2021 Sep; 9(1):e0029121. PubMed ID: 34406813
    [TBL] [Abstract][Full Text] [Related]  

  • 39. One-month humoral response following two or three doses of messenger RNA coronavirus disease 2019 vaccines as primary vaccination in specific populations in France: first results from the Agence Nationale Recherche contre le Sida (ANRS)0001S COV-POPART cohort.
    Loubet P; Wittkop L; Ninove L; Chalouni M; Barrou B; Blay JY; Hourmant M; Thouvenot E; Laville M; Laviolle B; Lelievre JD; Morel J; Quoc SN; Spano JP; Terrier B; Thiebaut A; Viallard JF; Vrtovsnik F; Circosta S; Esterle L; Levier A; Vanhems P; Tartour E; Parfait B; de Lamballerie X; Launay O;
    Clin Microbiol Infect; 2023 Mar; 29(3):388.e1-388.e8. PubMed ID: 36252789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Seroprevalence of anti-SARS-CoV-2 IgG antibodies pre- and post-COVID-19 vaccination in staff members of Bandar Abbas Children's Hospital.
    Tariverdi M; Mohammadi H; Hassanzadeh F; Tamaddondar M
    BMC Infect Dis; 2024 Feb; 24(1):253. PubMed ID: 38395759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.